PRKAG3

Across TCGA pan-cancer cohorts, PRKAG3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRKAG3 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher PRKAG3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRKAG3 expression acts as an unfavorable survival marker.

OV, LIHC, and CHOL are the cancer types where PRKAG3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.028	0.844	<.001	48	view →
LIHC	DFS	Median	All	0.091	0.553	.013	12	view →
CHOL	OS	Median	All	0.154	0.793	.004	9	view →
ESCA	OS	Median	II,III,IV	0.321	0.685	.035	6	view →
GBM	OS	Median	All	0.109	0.415	.032	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PRKAG3–OV (OS)

Open the OV breakdown →